185 related articles for article (PubMed ID: 12184168)
1. [Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].
de Freitas JA; Lima LM; Ranieri JL; Olivieri JC; Fragoso HJ; Chinzon D
Arq Gastroenterol; 2002; 39(1):60-5. PubMed ID: 12184168
[TBL] [Abstract][Full Text] [Related]
2. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
3. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Cloud ML; Enas N; Humphries TJ; Bassion S
Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
[TBL] [Abstract][Full Text] [Related]
4. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
[TBL] [Abstract][Full Text] [Related]
5. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Miner P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215
[TBL] [Abstract][Full Text] [Related]
6. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
7. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
[TBL] [Abstract][Full Text] [Related]
8. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
[TBL] [Abstract][Full Text] [Related]
9. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
10. Rabeprazole.
Prakash A; Faulds D
Drugs; 1998 Feb; 55(2):261-7; discussion 268. PubMed ID: 9506245
[TBL] [Abstract][Full Text] [Related]
11. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Feb; 13(2):179-86. PubMed ID: 10102948
[TBL] [Abstract][Full Text] [Related]
12. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Adachi K; Hashimoto T; Hamamoto N; Hirakawa K; Niigaki M; Miyake T; Taniura H; Ono M; Kaji T; Suetsugu H; Yagi J; Komazawa Y; Mihara T; Katsube T; Fujishiro H; Shizuku T; Hattori S; Yamamoto S; Kinoshita Y
J Gastroenterol Hepatol; 2003 Dec; 18(12):1392-8. PubMed ID: 14675268
[TBL] [Abstract][Full Text] [Related]
13. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rabeprazole once daily for acid-related disorders.
Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
[TBL] [Abstract][Full Text] [Related]
15. Review article: rabeprazole's tolerability profile in clinical trials.
Thjodleifsson B; Cockburn I
Aliment Pharmacol Ther; 1999 Oct; 13 Suppl 5():17-23. PubMed ID: 10555605
[TBL] [Abstract][Full Text] [Related]
16. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ
Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209
[TBL] [Abstract][Full Text] [Related]
18. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.
Breiter JR; Riff D; Humphries TJ
Am J Gastroenterol; 2000 Apr; 95(4):936-42. PubMed ID: 10763941
[TBL] [Abstract][Full Text] [Related]
19. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
20. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI
Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
